36915-02-3Relevant articles and documents
An efficient, economical synthesis of the novel anti-tumor agent CPI-613
Gibson, Frank S.,Gupta, Deepak,Shorr, Robert,Rodriguez, Robert
, p. 855 - 857 (2011)
An efficient and practical synthesis of the novel anti-tumor compound 6,8-dithiobenzyl octanoic acid, CPI-613 (2), was developed and executed on a practical scale. CPI-613 can be made in a single vessel from (±)-lipoic acid (1) via reductive opening of the disulfide ring followed by benzylation of the sulfhydryls with benzyl bromide. CPI-613 was isolated by simple crystallization in high yield and purity. The process is scaleable and has been demonstrated at up to 100 kg.
Method for synthesizing and preparing anti-tumor innovative drug, namely Devimistat
-
Paragraph 0023; 0026-0037, (2020/07/15)
The invention relates to a method for synthesizing and preparing an anti-tumor innovative drug, namely Devimidat. According to the preparation method for the Devimidat, after a process is improved, metal cobalt polysulfide does not need to be used any more; the process route is simple and convenient; the product, namely the Devimidat can be obtained through two steps which are performed through aone-pot method; and the preparation method has high yield and is applicable to large-scale production.
CPI-613: Antimitochondrial metabolism agent Treatment of hematological malignancies and solid tumors
Moro
, p. 209 - 214 (2017/05/17)
Metabolic changes specifically associated with cancer may constitute an excellent opportunity for the identification of new biomarkers and targets for novel drugs. The coenzyme lipoate is a key player in the control of cell metabolic fluxes and occupies a central position in tumor biology. Previous observations suggested that systemically delivered lipoate analogues might selectively disrupt cancer mitochondrial metabolism, potentially resulting in cancer cell death. CPI-613, the first member of a large set of lipoate analogues, specifically inhibits mitochondrial metabolism in a wide range of tumor cell lines, but not in normal cells, by mechanisms involving pyruvate dehydrogenase and α-ketoglutarate dehydrogenase enzyme complexes. There are 14 ongoing or completed phase I and phase II clinical trials on CPI-613, alone or in combination, showing promising results for several hematological malignancies and solid tumors, particularly for the treatment of acute myeloid leukemia, myelodysplastic syndrome and pancreatic cancer.
Aqueous-phase hydrogenation and hydroformylation reactions catalyzed by a new water-soluble [rhodium]-thioligand complex
Paganelli,Piccolo,Pontini,Tassini,Rathod
, p. 64 - 69 (2015/03/30)
Rh(DHTANa) is a new water-soluble catalyst easily obtained by mixing in water the catalytic precursor [Rh(COD)Cl]2 and the dihydrothioctic acid sodium salt (DHTANa). This catalyst showed to be very active in the hydrogenation of unsaturated substrates as 2-cyclohexen-1-one, the biomass-derived furfural and acetophenone. In this last case the catalytic system obtained by using as water-soluble ligand (R)-(DHTANa) afforded (R)-1-phenylethanol with very modest enantioselectivity. Rh(DHTANa) was active also in the aqueous biphase hydroformylation of styrene producing exclusively the two corresponding aldehydes with 80-86% selectivity toward the branched aldehyde 2-phenylpropanal. This new catalytic system was easily recycled in both hydrogenation and hydroformylation processes and no leaching phenomenon was observed.
